Article
Emergency Medicine
Colleen Elizabeth Howing, Farzad Razi, Wael Hakmeh
Summary: Ketamine may have a role in treating status epilepticus and can be considered as an induction agent for rapid sequence intubation or as a third or fourth line agent in refractory cases.
AMERICAN JOURNAL OF EMERGENCY MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Tzu-Hsin Huang, Ming-Chi Lai, Yu-Shiue Chen, Chin-Wei Huang
Summary: Status epilepticus (SE) is a neurological emergency with high mortality rate. The downregulation of GABAA receptors and upregulation of NMDA and AMPA receptors are the most widely accepted hypothesis underlying BZD resistance.
Article
Veterinary Sciences
Giulia Cagnotti, Sara Ferrini, Giorgia Di Muro, Eleonora Avilii, Alessandra Favole, Antonio D'Angelo
Summary: The aim of this study was to determine the effect of duration of anesthetic constant rate infusion (CRI) on outcome and length of hospital stay in dogs with refractory seizure activity of different etiology. There was no statistically significant difference found in outcomes between the experimental group and the control group. Shorter duration of anesthetic CRI did not have a clear superiority on outcome or length of hospital stay in dogs with refractory seizure activity of different etiology.
FRONTIERS IN VETERINARY SCIENCE
(2023)
Article
Clinical Neurology
Marin Jacobwitz, Caitlyn Mulvihill, Michael C. Kaufman, Alexander K. Gonzalez, Karla Resendiz, Jennifer M. MacDonald, Conall Francoeur, Ingo Helbig, Alexis A. Topjian, Nicholas S. Abend
Summary: This retrospective study analyzed the use of ketamine infusion for refractory status epilepticus (RSE) in pediatric patients. The results showed that ketamine was effective in reducing seizure frequency and had few adverse events.
Article
Emergency Medicine
Michael Perlmutter, Mark Price, Kathryn Kothari, Zubaid Rafique, Kelly Rogers Keene, Xavier De La Rosa, Elizabeth Weinstein, Casey Patrick
Summary: We present a study on six pediatric patients treated with ketamine for benzodiazepine-resistant status epilepticus in an urban emergency medical services system. Ketamine has shown efficacy as a second-line agent for refractory seizures in both adults and children, and a low-cost option for prehospital treatment is highly desirable. Initial data suggests that ketamine may provide promising seizure control effects without significant respiratory depression in pediatric patients with benzodiazepine-refractory seizures, demonstrating its potential role in EMS treatment.
PREHOSPITAL EMERGENCY CARE
(2023)
Article
Multidisciplinary Sciences
Mehdi Sanatkar, Zohre Nozarian, Fatemeh Bazvand, Parisa Abdi
Summary: This study aimed to determine the safety of topical ketamine for the cornea and evaluate its effect on the repair process of damaged corneal tissue. The results showed that topical ketamine had no significant effect on corneal wound healing in a rat animal model.
SCIENTIFIC REPORTS
(2022)
Article
Veterinary Sciences
Patrick Roynard, Ann Bilderback, Curtis Wells Dewey
Summary: Ketamine 5 mg/kg IV bolus may be successful in treating RSE in dogs, but its efficacy in handling CS is limited. The incidence of adverse effects is low, but timing of administration should be carefully considered.
FRONTIERS IN VETERINARY SCIENCE
(2021)
Article
Neurosciences
Panos Zanos, Kyle A. Brown, Polymnia Georgiou, Peixiong Yuan, Carlos A. Zarate Jr, Scott M. Thompson, Todd D. Gould
Summary: Ketamine, a well-known NMDA receptor antagonist, exerts rapid antidepressant effects by enhancing excitatory synaptic strength. These findings suggest that promoting NMDA receptor activation or enhancing NMDA receptor-dependent synaptic potentiation may be an effective strategy for antidepressant treatment.
JOURNAL OF NEUROSCIENCE
(2023)
Article
Multidisciplinary Sciences
Ji-Woon Kim, Joachim Herz, Ege T. Kavalali, Lisa M. Monteggia
Summary: This study investigated whether disruptions in Reelin-mediated synaptic signaling alter ketamine-triggered synaptic plasticity and behavioral effects. The findings suggest that impairments in Reelin-Apoer2-SFK pathway components may in part underlie nonresponsiveness to ketamine's antidepressant action.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Review
Neurosciences
Divya Choudhury, Anita E. Autry, Kimberley F. Tolias, Vaishnav Krishnan
Summary: Ketamine, a non-competitive NMDAR antagonist, has been used as an intravenous anesthetic since the 1970s and is now being explored for its rapid antidepressant effects in treating various neuropsychiatric syndromes. Studies have shown that ketamine exhibits both neurotoxic and neuroprotective properties depending on the context, affecting intracellular signaling pathways in complex ways. It acts as a powerful activator of neurotrophic signaling cascades at subanesthetic doses, showcasing contrasting neuroprotective and neurotoxic characteristics.
FRONTIERS IN NEUROSCIENCE
(2021)
Article
Veterinary Sciences
Giulia Cagnotti, Sara Ferrini, Giorgia Di Muro, Giuliano Borriello, Cristiano Corona, Luca Manassero, Eleonora Avilii, Claudio Bellino, Antonio D'Angelo
Summary: The study investigated the use of constant rate infusion of benzodiazepines or propofol in dogs with epilepsy. The medications appeared to be well-tolerated and effective in controlling seizure activity in most patients, regardless of seizure etiology. Further research is needed to assess the effects of CRI duration on outcomes and complications.
FRONTIERS IN VETERINARY SCIENCE
(2022)
Article
Clinical Neurology
Xiangzhen Tong, Zizhu Zhang, Jianping Zhu, Shuji Li, Shaogang Qu, Bing Qin, Yanwu Guo, Rongqing Chen
Summary: Research suggests that using midazolam to terminate status epilepticus can provide better protection against epileptogenesis compared to diazepam and pentobarbital. Therefore, midazolam can be considered as the first choice anti-status epilepticus medication, providing additional benefits against epileptogenesis.
FRONTIERS IN NEUROLOGY
(2022)
Article
Behavioral Sciences
Lisa Coles, Eric S. Rosenthal, Thomas P. Bleck, Jordan Elm, Shahriar Zehtabchi, James Chamberlain, James Cloyd, Shlomo Shinnar, Robert Silbergleit, Jaideep Kapur
Summary: This paper presents the rationale for testing ketamine as an add-on therapy for treating benzodiazepine refractory status epilepticus. Animal studies have shown that ketamine can terminate refractory status epilepticus by interfering with the pathophysiological mechanisms and providing neuroprotection. Ketamine does not suppress respiration when used for sedation and anesthesia. Reports suggest that ketamine can help terminate refractory and super refractory status epilepticus. The recommended dosage is 1 or 3 mg/kg intravenous ketamine based on animal-to-human conversion and pharmacokinetic studies. This paper was presented at the 8th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures held in September 2022. (c) 2022 Elsevier Inc. All rights reserved.
EPILEPSY & BEHAVIOR
(2023)
Article
Biochemistry & Molecular Biology
Ying Chen, Wenqing Xu, Yuan Yuan, Houyang Chen, Shuangyan Zheng, Yuanqiao He, Tao Luo
Summary: The study found that the N-methyl-D-aspartic acid receptor may be involved in the inhibitory effect of ketamine on human sperm function, while NMDA can reverse the inhibitory effect of ketamine.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Medicine, Research & Experimental
Ruijiao Zhou, Yanlin Wang, Xing Cao, Zhimin Li, Juming Yu
Summary: Diazepam monotherapy can terminate seizures and improve survival rates within 10 minutes of SE onset, while diazepam-ketamine dual therapy can terminate seizures and achieve high survival rates when SE lasts more than 10 minutes but less than 30 minutes.
MEDICAL SCIENCE MONITOR
(2021)
Article
Cell Biology
Guangfu Wang, Genrieta Bochorishvili, Yucai Chen, Kathryn A. Salvati, Peng Zhang, Steve J. Dubel, Edward Perez-Reyes, Terrance P. Snutch, Ruth L. Stornetta, Karl Deisseroth, Alev Erisir, Slobodan M. Todorovic, Jian-Hong Luo, Jaideep Kapur, Mark P. Beenhakker, J. Julius Zhu
GENES & DEVELOPMENT
(2015)
Article
Clinical Neurology
Ewa Lewczuk, Suchitra Joshi, John Williamson, Mouna Penmetsa, Sarah Shan, Jaideep Kapur
Article
Clinical Neurology
Suchitra Joshi, Karthik Rajasekaran, John Williamson, Jaideep Kapur
Article
Neurosciences
Suchitra Joshi, Karthik Rajasekaran, Huayu Sun, John Williamson, Jaideep Kapur
NEUROBIOLOGY OF DISEASE
(2017)
Editorial Material
Clinical Neurology
Thomas Wychowski, Jaideep Kapur
Editorial Material
Clinical Neurology
Barbara A. Dworetzky, Jaideep Kapur
Article
Clinical Neurology
Terry Zhang, Marko S. Todorovic, John Williamson, Jaideep Kapur
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2017)
Review
Neurosciences
Suchitra Joshi, Jaideep Kapur
Article
Neurosciences
Suchitra Joshi, Huayu Sun, Karthik Rajasekaran, John Williamson, Edward Perez-Reyes, Jaideep Kapur
NEUROBIOLOGY OF DISEASE
(2018)
Article
Computer Science, Interdisciplinary Applications
Haoyi Liang, Natalia Dabrowska, Jaideep Kapur, Daniel S. Weller
IEEE TRANSACTIONS ON MEDICAL IMAGING
(2019)
Review
Behavioral Sciences
John Williamson, Tanveer Singh, Jaideep Kapur
EPILEPSY & BEHAVIOR
(2019)
Article
Behavioral Sciences
Hannah R. Cock, Lisa D. Coles, Jordan Elm, Robert Silbergleit, James M. Chamberlain, James C. Cloyd, Nathan Fountain, Shlomo Shinnar, Dan Lowenstein, Robin Conwit, Thomas P. Bleck, Jaideep Kapur
EPILEPSY & BEHAVIOR
(2019)
Article
Medicine, General & Internal
James M. Chamberlain, Jaideep Kapur, Shlomo Shinnar, Jordan Elm, Maija Holsti, Lynn Babcock, Alex Rogers, William Barsan, James Cloyd, Daniel Lowenstein, Thomas P. Bleck, Robin Conwit, Caitlyn Meinzer, Hannah Cock, Nathan B. Fountain, Ellen Underwood, Jason T. Connor, Robert Silbergleit
Article
Oncology
Andrew C. Schomer, Jaideep Kapur
ANNALS OF TRANSLATIONAL MEDICINE
(2016)
Article
Clinical Neurology
Suchitra Joshi, Jaideep Kapur